Carbamazepine extended-release capsules for the treatment of bipolar I disorder

Therapy

Volumn 2, Issue 4, 2005, Pages 533-544

  Weisler, Richard H ^a,b  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bipolar disorder; Carbamazepine extended; Mania

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CIMETIDINE; CISPLATIN; CLARITHROMYCIN; DANAZOL; DEXTROPROPOXYPHENE; DILTIAZEM; DOXORUBICIN; ERYTHROMYCIN; FELBAMATE; ISONIAZID; KETOCONAZOLE; LITHIUM SALT; LORATADINE; LORAZEPAM; MACROLIDE; NICOTINAMIDE; OLANZAPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; RIFAMPICIN; TERFENADINE; THEOPHYLLINE; TROLEANDOMYCIN; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ATAXIA; BIPOLAR I DISORDER; BIPOLAR MANIA; BODY WEIGHT DISORDER; BONE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG COMPETITION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG OXIDATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ECG ABNORMALITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERANDROGENISM; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LIVER TOXICITY; META ANALYSIS; MIXED MANIA AND DEPRESSION; NAUSEA; OVARY POLYCYSTIC DISEASE; PANCREATITIS; PATIENT COMPLIANCE; PRURITUS; PSYCHOTHERAPY; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; TERATOGENICITY; VOMITING; WEIGHT GAIN;

EID: 22544452109     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.4.533     Document Type: Review

References (80)

1. Bostwick JM Pankratz VS. Affective disorders and suicide risk: a re-examination. Am. J. Psychiat. 157(12), 1925-1932 (2000).
2. Judd LL Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 73(1-2), 123-131 (2003).
3. Das AK, Olfson M, Gameroff MJ et al. Screening for bipolar disorder in a primary care practice. J. Am. Med. Assoc. 293(8), 956-963 (2005).
4. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J. Affect. Disord. 50(2-3), 143-151 (1998).
5. Theobald W Kunz HA. On the pharmacology of the anti-epileptic 5-carbamyl-5H-dibenzo (b,f)azepine. ArzneimittelForschung 13, 122-125 (1963).
6. Okuma T Kishimoto A. A history of investigation on the mood stabilizing effect of carbamazepine in Japan. Psychiat. Clin. Neurosci. 52(1), 3-12 (1998).
7. Takezaki H Hanaoka M. The use of carbamazepine (Tegretol) in the control of manic depressive psychosis and other manic depressive psychosis. Seishin Igaku 13, 1310-1318 (1971).
8. Okuma T, Kishimoto A, Inoue K, Matsumoto H, Ogura A. Antimanic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatr. Neurol. Jpn 27(4), 283-297 (1973).
9. Post RM Kopanda RT. Cocaine, kindling, and psychosis. Am. J. Psychiatry. 133(6), 627-634 (1976).
10. Post RM, Uhde TW, Putnam FW, Ballenger JC, Berrettini WH. Kindling and carbamazepine in affective illness. J. Nerv. Ment. Dis. 170(12), 717-731 (1982).
11. Ballenger JC Post RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun. Psychopharmacol. 2(2), 159-175 (1978).
12. Ballenger JC Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am. J. Psychiat. 137(7), 782-790 (1980).
13. American Psychiatric Association Steering Committee on Practice Guidelines: Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiat. 159(Suppl. 4), 1-50 (2002).
14. Mitchell PB Malhi GS. The expanding Pharmacopeia for bipolar disorder. Ann. Rev. Med. 53, 173-188 (2002).
15. Levine J, Chengappa KNR, Brar JS et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord. 2, 120-130 (2000).
16. Belmaker RH. Bipolar disorder. N. Engl. J. Med. 351(5), 476-486 (2004).
17. Lithotwice daily®, prescribing information. Solvay Pharmaceuticals, GA, USA.
18. Dunner DL, Fleiss JL, Fieve RR. Lithium carbonate prophylaxis failure. Br. J. Psychiat. 129, 40-44 (1976).
19. Denicoff KD, Smith-Jackson EE, Disney ER et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J. Clin. Psychiat. 58(11), 470-478 (1997).
20. Prien RF, Klett CJ, Caffey EM, Jr. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch. Gen. Psychiat. 29(3), 420-425 (1973).
21. Macritchie K, Geddes JR, Scott J et al. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst. Rev. 1, CD004052 (2004).
22. McElroy SL, Frye MA, Suppes T et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J. Clin. Psychiat. 63(3), 207-213 (2002).
23. Depakote®, prescribing information. Abbott Laboratories, IL, USA.
24. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N. Engl. J. Med. 329(19), 1383-1388 (1993).
25. Joffe RT, Cohen L, Suppes T et al. Polycystic ovarian syndrome is associated with valproate use in bipolar women (2004).
26. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N. Engl. J. Med. 329(19), 1383-1388 (1993).
27. Boluk A, Guzelipek M, Savli H et al.: The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol. Res. 50(1), 93-97 (2004).
28. Equetro™, prescribing information. Shire, PA, USA.
29. Kerr BM, Thummel KE, Wurden CJ et al.: Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10, 11-poxide formation. Biochem. Pharmacol. 47(11), 1969-1979 (1994).
30. Frigerio A Morselli PL. Carbamazepine. Biotransformation 295-308 (1975).
31. Faigle JW, Feldmann KF, Baltzer V. Anticonvulsant effect of carbamazepine: an attempt to distinguish between the potency of the parent drug and its epoxide metabolite. 104-108 (1977).
32. MacDonald R. Carbamazepine: mechanisms of action, fifth edition 20, 227-235 (2002).
33. Willow M Catterall WA. Inhibition of binding of [3H] batrachotoxinin A 20-α-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 22(3), 627-635 (1982).
34. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem. Res. 27(1-2), 121-130 (2002).
35. Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 25(2), 228-234 (1984).
36. 2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 38(9), 1349-1359 (1999).
37. Schirrmacher K, Mayer A, Walden J, Dusing R, Bingmann D. Effects of carbamazepine on action potentials and calcium currents in rat spinal ganglion cells in vitro. Neuropsychobiology 27(3), 176-179 (1993).
38. Yan QS, Mishra PK, Burger RL et al.: Evidence that carbamazepine and anti-epilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsyprone rats. J. Pharmacol. Exp. Ther. 261(2), 652-659 (1992).
39. 2+. Eur. J. Pharmacol. 328(2-3), 153-162 (1997).
40. Dailey JW, Reith ME, Steidley KR, Milbrandt JC, Jobe PC. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 39(10), 1054-1063 (1998).
41. Olpe HR, Baudry M, Jones RS. Electrophysiological and neurochemical investigations on the action of carbamazepine on the rat hippocampus. Eur. J. Pharmacol. 110(1), 71-80 (1985).
42. Waldmeier PC, Baumann PA, Wicki P et al.: Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 45(10), 1907-1913 (1995).
43. Li X, Ketter TA, Frye MA. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J. Affect. Disord. 69(1-3), 1-14 (2002).
44. Lampe H Bigalke H. Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport 1(1), 26-28 (1990).
45. Myllyla VV. Effect of convulsions and anticonvulsive drugs on cerebrospinal fluid cyclic AMP in rabbits. Eur. Neurol. 14(2), 97-107 (1976).
46. Palmer GC, Jones DJ, Medina MA, Stavinoha WB. Anticonvulsant drug actions on in vitro and in vivo levels of cyclic AMP in the mouse brain. Epilepsia 20(2), 95-104 (1979).
47. Hudson CJ, Young LT, Li PP, Warsh JJ. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse. 13(3), 278-293 (1993).
48. McLean A, Browne S, Zhang Y et al.: The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation. J. Clin. Pharmacol. 41(2), 183-186 (2001).
49. Hoppener RJ, Kuyer A, Meijer JW, Hulsman J. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 21(4), 341-350 (1980).
50. Riva R, Albani F, Ambrosetto G et al.: Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 25(4), 476-481 (1984).
51. Schmidt D Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type. Neurology 34(9), 1252-1255 (1984).
52. Tomson T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch. Neurol. 41(8), 830-834 (1984).
53. Ghose K, Fry DE, Christfides JA. Effect of dosage frequency of carbamazepine on drug serum levels in epileptic patients. Eur. J. Clin. Pharmacol. 24(3), 375-381 (1983).
54. Macphee GJ, Butler E, Brodie MJ. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism. Epilepsia 28(3), 286-294 (1987).
55. Keck PE, Jr., McElroy SL, Strakowski SM, Bourne ML, West SA. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol. Bull. 33(1), 87-91 (1997).
56. Keck PE, Jr., McElroy SL, Strakowski SM et al. Factors associated with pharmacologic noncompliance in patients with mania. J. Clin. Pychiat. 57(7), 292-297 (1996).
57. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. J. Am. Med. Assoc. 261(22), 3273-3277 (1989).
58. Eichelbaum M, Kothe KW, Hoffmann F, von Unruh GE. Use of stable labelled carbamazepine to study its kinetics during chronic carbamazepine treatment. Eur. J Clin. Pharmacol. 23(3), 241-244 (1982).
59. Cloyd JC Remmel RP. Anti-epileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy. Pharmacotherapy. 20(8 Pt 2), 139S-151S (2000).
60. Stevens RE, Limsakun T, Evans G, Mason DH, Jr.: Controlled, multhree-times dailyose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR). J Pharm. Sci. 87(12), 1531-1534 (1998).
61. Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand. 109(6), 374-377 (2004).
62. Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand. 109(6), 374-377 (2004).
63. Weisler RH, Kalali AH, Ketter TA, and the SPD417 Study Group: A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J. Clin. Psychiat. 65, 478-484 (2004).
64. Weisler RH, Keck PE, Swann AC et al.: Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Pychiat. 66(3), 323-330 (2005).
65. Ketter TA, Kalali AH, Weisler RH, for the SPD417 Study Group: A 6-month, multicenter, open-label evaluation of extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J. Clin. Psychiat. 65, 668-673 (2004).
66. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiat. Res. 73(3), 159-171 (1997).
67. Hamilton M. A Rating Scale for Depression. J. Neurol. Neurosurg. Psychiat. 23, 56-59 (1960).
68. Weisler RH, Hirschfeld R, Cutler AJ et al. Safety and tolerability of extended-release carbamazepine in bipolar disorder: results from 2 pooled clinical trials. Presented at: US Psychiatric and Mental Health Congress November 18-21, 2004 San Diego, CA, USA (2004).
69. Weisler RH, Hirschfeld R, Cutler AJ et al. Efficacy of extended-release carbamazepine in bipolar disorder: results of two pooled clinical trials. Presented at: US Psychiatric and Mental Health Congress November 18-21, 2004 San Diego, CA, USA (2004).
70. Montgomery SA, Schatzberg AF, Guelfi JD et al. Pharmacotherapy of depression and mixed states in bipolar disorder. J. Affect. Disord. 59 Suppl. 1, S39-S56 (2000).
71. Prien RF, Himmelhoch JM, Kupfer DJ. Treatment of mixed mania. J. Affect. Disord. 15(1), 9-15 (1988).
72. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Anthree-times dailyepressant effects of carbamazepine. Am. J. Psychiat. 143(1), 29-34 (1986).
73. Dilsaver SC, Swann SC, Chen YW et al. Treatment of bipolar depression with carbamazepine: results of an open study. Biol. Psychiat. 40(9), 935-937 (1996).
74. Shire US, Inc. Wayne, PA-(2005).
75. Bowden CL, Brugger AM, Swann AC et al.: Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote Mania Study Group. J. Am. Med. Assoc. 271(12), 918-924 (1994).
76. Lindenmayer JP, Czobor P, Volavka J et al.: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiat. 160(2), 290-296 (2003).
77. Wirshing DA, Boyd JA, Meng LR et al.: The effects of novel antipsychotics on glucose and lipid levels. J. Clin. Psychiat. 63(10), 856-865 (2002).
78. Sussman N. Review of atypical antipsychotics and weight gain. J. Clin. Psychiat. 62 Suppl. 23, 5-12 (2001).
79. McElroy SL Keck PE, Jr.: Pharmacologic agents for the treatment of acute bipolar mania. Biol. Psychiat. 48(6), 539-557 (2000).
80. Health implications of obesity. National Institutes of Health Consensus Development Conference Statement. Ann. Intern. Med. 103(6 (Pt 2)), 1073-1077 (1985).